205676-87-5Relevant academic research and scientific papers
C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE
-
Paragraph 00165, (2015/02/19)
The present invention provides compositions and methods for the selective C-H fluorination of nitrogen-containing heteroarenes with AgF2, which has previously been considered too reactive for practical, selective C-H fluorination. Fluorinated heteroarenes are prevalent in numerous pharmaceuticals, agrochemicals and materials. However, the reactions used to introduce fluorine into these molecules require pre-functionalized substrates or the use of F2 gas. The present invention provides a mild and general method for the C-H fluorination of nitrogen-containing heteroarene compounds to 2-fluoro-heteroarenes with commercially available AgF2. In various embodiments, these reactions occur at ambient temperature within one hour and occur with exclusive selectivity for fluorination at the 2-position. Exemplary reaction conditions are effective for fluorinating diazine heteroarenes to form a single fluorinated isomer.
Synthesis and late-stage functionalization of complex molecules through C-H fluorination and nucleophilic aromatic substitution
Fier, Patrick S.,Hartwig, John F.
, p. 10139 - 10147 (2014/08/05)
We report the late-stage functionalization of multisubstituted pyridines and diazines at the position α to nitrogen. By this process, a series of functional groups and substituents bound to the ring through nitrogen, oxygen, sulfur, or carbon are installed. This functionalization is accomplished by a combination of fluorination and nucleophilic aromatic substitution of the installed fluoride. A diverse array of functionalities can be installed because of the mild reaction conditions revealed for nucleophilic aromatic substitutions (SNAr) of the 2-fluoroheteroarenes. An evaluation of the rates for substitution versus the rates for competitive processes provides a framework for planning this functionalization sequence. This process is illustrated by the modification of a series of medicinally important compounds, as well as the increase in efficiency of synthesis of several existing pharmaceuticals.
Design, synthesis, and biological evaluation of novel potent and selective αvβ3/αvβ5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core
Marugán, Juan José,Manthey, Carl,Anaclerio, Beth,Lafrance, Lou,Lu, Tianbao,Markotan, Tom,Leonard, Kristi A.,Crysler, Carl,Eisennagel, Stephen,Dasgupta, Malini,Tomczuk, Bruce
, p. 926 - 934 (2007/10/03)
A novel series of potent and selective αvβ 3/αvβ5 dual inhibitors was designed, synthesized, and evaluated against several integrins. These compounds were synthesized through a Mitsunobu reaction between the gua
VITRONECTIN RECEPTOR ANTAGONISTS
-
Page 21, (2010/02/09)
Compounds of formula (I) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis wherein R is Het- or Ar; R is formula (a) or formula (b); or a pharmaceutically acceptable salt thereof.
PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES
-
Page 28-29; 39-40, (2010/02/09)
Disclosed is a new process and intermediates for preparing benzazepines of Formula wherein R1 and R2 are as defined herein.
Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
-
, (2008/06/13)
The present invention relates to novel substituted benzofurans and benzothiophenes compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable
Substituted indoles and their use as integrin antagonists
-
, (2008/06/13)
The present invention relates to novel substituted indole compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
